HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis

Prostate

Volumn 72, Issue 1, 2012, Pages 90-99

  Zhang, Zhi Yuan ^a   Schluesener, Hermann J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

experimental autoimmune prostatitis; HDAC inhibitor; M2 macrophage; MS 275; Treg cell

Indexed keywords

ENTINOSTAT; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE; MACROPHAGE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE; PROSTATITIS; RAT; REGULATORY T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; BENZAMIDES; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE INHIBITORS; IMMUNITY, CELLULAR; INFLAMMATION; MALE; PROSTATE; PROSTATITIS; PYRIDINES; RATS; RATS, INBRED LEW; T-LYMPHOCYTES, REGULATORY;

EID: 81855194108     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21410     Document Type: Article

References (43)

1. Penna G, Fibbi B, Maggi M, Adorini L,. Prostate autoimmunity: From experimental models to clinical counterparts. Expert Rev Clin Immunol 2009; 5: 577-586.
2. Motrich RD, Maccioni M, Riera CM, Rivero VE,. Autoimmune prostatitis: State of the art. Scand J Immunol 2007; 66: 217-227.
3. Litwin MS,. A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology 2002; 60: 14-18.
4. Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH,. Epidemiology of prostatitis: New evidence for a world-wide problem. World J Urol 2003; 21: 70-74.
5. Corman JM, Sercarz EE, Nanda NK,. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 1998; 114: 166-172.
6. Kouiavskaia DV, Southwood S, Berard CA, Klyushnenkova EN, Alexander RB,. T-cell recognition of prostatic peptides in men with chronic prostatitis/chronic pelvic pain syndrome. J Urol 2009; 182: 2483-2489.
7. Ludwig M, Steltz C, Huwe P, Schäffer R, Altmannsberger M, Weidner W,. Immunocytological analysis of leukocyte subpopulations in urine specimens before and after prostatic massage. Eur Urol 2001; 39: 277-282.
8. Motrich RD, Cuffini C, Oberti JP, Maccioni M, Rivero VE,. Chlamydia trachomatis occurrence and its impact on sperm quality in chronic prostatitis patients. J Infect 2006; 53: 175-183.
9. Alexander RB, Brady F, Ponniah S,. Autoimmune prostatitis: Evidence of T cell reactivity with normal prostatic proteins. Urology 1997; 50: 893-899.
10. Batstone GR, Doble A, Gaston JS,. Autoimmune T cell responses to seminal plasma in chronic pelvic pain syndrome (CPPS). Clin Exp Immunol 2002; 128: 302-307.
11. Ponniah S, Arah I, Alexander RB,. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000; 44: 49-54.
12. Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, Rivero VE,. Presence of INFγ-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 2005; 116: 149-157.
13. Penna G, Amuchastegui S, Cossetti C, Aquilano F, Mariani R, Sanvito F, Doglioni C, Adorini L,. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol 2006; 177: 8504-8511.
14. Vykhovanets EV, Resnick MI, MacLennan GT, Gupta S,. Experimental rodent models of prostatitis: Limitations and potential. Prostate Cancer Prostatic Dis 2007; 10: 15-29.
15. Rudick CN, Schaeffer AJ, Thumbikat P,. Experimental autoimmune prostatitis induces chronic pelvic pain. Am J Physiol Regul Integr Comp Physiol 2008; 294: 1268-1275.
16. Hess-Stumpp H, Bracker TU, Henderson D, Politz O,. MS-275, a potent orally available inhibitor of histone deacetylases-The development of an anticancer agent. Int J Biochem Cell Biol 2007; 39: 1388-1405.
17. Lin HY, Chen CS, Lin SP, Weng JR, Chen CS,. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006; 26: 397-413.
18. Li Y, Yuan Z, Liu B, Sailhamer EA, Shults C, Velmahos GC, Demoya M, Alam HB,. Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition. J Trauma 2008; 64: 863-870.
19. Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA,. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005; 10: 3912-3922.
20. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ,. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008; 65: 4055-4065.
21. Sawalha AH,. Epigenetics and T-cell immunity. Autoimmunity 2008; 41: 245-252.
22. Su RC, Becker AB, Kozyrskyj AL, Hayglass KT,. Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 2008; 121: 57-63.
23. Blanchard F, Chipoy C,. Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discov Today 2005; 10: 197-204.
24. Lin HS, Hu CY, Chan HY, Liew YY, Huang HP, Lepescheux L, Bastianelli E, Baron R, Rawadi G, Clément-Lacroix P,. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007; 150: 862-872.
25. Zhang ZY, Zhang Z, Schluesener HJ,. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 2010; 169: 370-377.
26. Nencioni A, Beck J, Werth D, Grünebach F, Patrone F, Ballestrero A, Brossart P,. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007; 13: 3933-3941.
27. Zhang ZY, Zug C, Schluesener HJ,. Sphingosine 1-phosphate receptor modulator FTY720 suppresses rat experimental autoimmune prostatitis. Scand J Immunol 2011 [Epub ahead of print]. DOI: 10.1111/j.1365-3083.2011.02528.x
28. Vandooren B, Noordenbos T, Ambarus C, Krausz S, Cantaert T, Yeremenko N, Boumans M, Lutter R, Tak PP, Baeten D,. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009; 60: 966-975.
29. Shahbazian MD, Grunstein M,. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76: 75-100.
30. Glauben R, Sonnenberg E, Zeitz M, Siegmund B,. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009; 280: 154-159.
31. Adcock IM,. Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 2006; 7: 966-973.
32. Zhang Z, Zhang ZY, Fauser U, Schluesener HJ,. Distribution of Foxp3(+) T-regulatory cells in experimental autoimmune neuritis rats. Exp Neurol 2009; 216: 75-82.
33. Zhou XH, Li LD, Wu LM, Han L, Liu ZD, Yang JX, Lv YW, You CL, Zhou ZH,. Increased inflammatory factors activity in model rats with experimental autoimmune prostatitis. Arch Androl 2007; 53: 49-52.
34. Rivero V, Carnaud C, Riera CM,. Prostatein or steroid binding protein (PSBP) induces experimental autoimmune rostatitis (EAP) in NOD mice. Clin Immunol 2002; 105: 176-184.
35. Aranami T, Yamamura T,. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008; 57: 115-120.
36. Steiner GE, Newman ME, Paikl D, Stix U, Memaran-Dagda N, Lee C, Marberger MJ,. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56: 171-182.
37. Kramer G, Marberger M,. Could inflammation be a key component in the progression of benign prostatic hyperplasia? Curr Opin Urol 2006; 16: 25-29.
38. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG,. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008; 14: 3254-3261.
39. Tinker AC, Wallace AV,. Selective inhibitors of inducible nitric oxide synthase: Potential agents for the treatment of inflammatory diseases? Curr Top Med Chem 2006; 6: 77-92.
40. O'Connor RA, Anderton SM,. Multi-faceted control of autoaggression: Foxp3+ regulatory T cells in murine models of organ-specific autoimmune disease. Cell Immunol 2008; 251: 8-18.
41. Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP,. Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009; 257: 97-104.
42. Morõn G, Maletto B, Orsilles M, Depiante-Depaoli M, Pistoresi-Palencia MC,. Age-related alterations in inflammatory response during experimental autoimmune prostatitis. Mech Ageing Dev 2000; 118: 71-85.
43. Han SB, Lee JK,. Anti-inflammatory effect of Trichostatin-A on murine bone marrow-derived macrophages. Arch Pharm Res 2009; 32: 613-624.